Hong Kong Express saw a passenger volume increase of over 40% in 2024, with a record-high of 6 million passengers carried throughout the year.
Cathay Pacific Airways subsidiary budget airline HK Express announced that the company's full-year passenger volume in 2024 increased by 40% year-on-year, and welcomed the 6 millionth passenger of the year on December 31, setting a new record for the highest annual passenger volume in the company's history.
CATHAY PAC AIR (00293) announced that its budget airline, Hong Kong Express, saw a 40% year-on-year increase in passenger capacity in 2024, and welcomed its 6 millionth annual passenger on December 31, setting a new record for the highest annual passenger volume. Hong Kong Express also cited the travel data platform OAG, which named the company the global "fastest growing airline of 2024".
According to data from the OAG website, the platform evaluates growth rates based on the number of flights, and Hong Kong Express operated around 35,000 flights in 2024, a 46% increase from 23,900 flights in 2023.
Eva Mok, CEO of Hong Kong Express, stated that the company is actively expanding its route network, increasing its fleet size, and strengthening its entire team. As Hong Kong's only low-cost airline, the company will continue to offer affordable fares and new destinations to provide more opportunities for passengers to explore Asia and fulfill their travel dreams. She looks forward to making further contributions to Hong Kong's aviation and tourism industries in the future, and collectively consolidating Hong Kong's position as an international aviation hub.
Related Articles

ZHONGSHENJIANYE (02503): The subscription price has been changed to HKD 0.61 per share. Trading will resume at 1:00 pm on July 3rd.

SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.

SIRNAOMICS-B (02257): Ouyang Yunlong appointed as non-executive director.
ZHONGSHENJIANYE (02503): The subscription price has been changed to HKD 0.61 per share. Trading will resume at 1:00 pm on July 3rd.

SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.

SIRNAOMICS-B (02257): Ouyang Yunlong appointed as non-executive director.

RECOMMEND

U.S. Senate Passes “Big and Beautiful” Bill, Triggering Surge in Gold Amid Soaring Deficit Concerns
02/07/2025

Declining Demand Triggers Price Drop; Photovoltaic Glass Industry May Be Preparing for a New Round of Coordinated Production Cuts
02/07/2025

Surge in Prices of Chinese-Made Goods Highlights Tariff Impact on U.S. Consumers
02/07/2025